BACKGROUND:Stroke is a rare but potentially devastating complication of acute myocardial infarction. Little is known about stroke timing, characteristics, and clinical outcomes in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention (PCI). METHODS AND RESULTS: We studied 5372 patients enrolled in the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. We analyzed stroke incidence, type, timing, and association with the prespecified 90-day clinical outcomes. Cox proportional hazards modeling was performed to assess the relationship between stroke and outcomes, after adjusting baseline characteristics and analyzing stroke as a time-dependent covariate. Stroke occurred in 69 primary patients with PCI (1.3%). A third of strokes were ischemic (n=23; 33%), 12% (n=8) were hemorrhagic, and the remaining 55% (n=38) were of uncertain type. The median (25th, 75th percentile) time of stroke occurrence was 6 (3, 14) days. Overall, 43% of strokes occurred within 48 hours of PCI, and all hemorrhagic strokes occurred within 48 hours. Stroke was associated with an increased risk of 90-day death (unadjusted hazard ratio [HR], 8.0; 95% confidence interval [CI], 4.8-13.5), congestive heart failure (unadjusted HR, 3.2; 95% CI, 1.3-7.8), and 30-day hospital readmission (unadjusted HR, 3.2; 95% CI, 2.0-5.1). After adjustment, stroke was still strongly associated with 90-day death (adjusted HR, 5.6; 95% CI, 3.2-9.8) and the combination end point of death, congestive heart failure, or cardiogenic shock at 90 days (adjusted HR, 2.4; 95% CI, 1.2-4.7). CONCLUSIONS:Stroke is an infrequent complication in the setting of ST-segment elevation myocardial infarction treated with primary PCI but is associated with increased morbidity and mortality. Studies to determine mechanisms that may be responsible for strokes that occur >48 hours from primary PCI are warranted. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00091637.
RCT Entities:
BACKGROUND:Stroke is a rare but potentially devastating complication of acute myocardial infarction. Little is known about stroke timing, characteristics, and clinical outcomes in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention (PCI). METHODS AND RESULTS: We studied 5372 patients enrolled in the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. We analyzed stroke incidence, type, timing, and association with the prespecified 90-day clinical outcomes. Cox proportional hazards modeling was performed to assess the relationship between stroke and outcomes, after adjusting baseline characteristics and analyzing stroke as a time-dependent covariate. Stroke occurred in 69 primary patients with PCI (1.3%). A third of strokes were ischemic (n=23; 33%), 12% (n=8) were hemorrhagic, and the remaining 55% (n=38) were of uncertain type. The median (25th, 75th percentile) time of stroke occurrence was 6 (3, 14) days. Overall, 43% of strokes occurred within 48 hours of PCI, and all hemorrhagic strokes occurred within 48 hours. Stroke was associated with an increased risk of 90-day death (unadjusted hazard ratio [HR], 8.0; 95% confidence interval [CI], 4.8-13.5), congestive heart failure (unadjusted HR, 3.2; 95% CI, 1.3-7.8), and 30-day hospital readmission (unadjusted HR, 3.2; 95% CI, 2.0-5.1). After adjustment, stroke was still strongly associated with 90-day death (adjusted HR, 5.6; 95% CI, 3.2-9.8) and the combination end point of death, congestive heart failure, or cardiogenic shock at 90 days (adjusted HR, 2.4; 95% CI, 1.2-4.7). CONCLUSIONS:Stroke is an infrequent complication in the setting of ST-segment elevation myocardial infarction treated with primary PCI but is associated with increased morbidity and mortality. Studies to determine mechanisms that may be responsible for strokes that occur >48 hours from primary PCI are warranted. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00091637.
Authors: Dhanuka Perera; Krishnaraj S Rathod; Oliver Guttmann; Anne-Marie Beirne; Constantinos O'Mahony; Roshan Weerackody; Andreas Baumbach; Anthony Mathur; Andrew Wragg; Daniel A Jones Journal: Am J Cardiovasc Dis Date: 2020-12-15
Authors: Sanjit S Jolly; John A Cairns; Salim Yusuf; Brandi Meeks; Janice Pogue; Michael J Rokoss; Sasko Kedev; Lehana Thabane; Goran Stankovic; Raul Moreno; Anthony Gershlick; Saqib Chowdhary; Shahar Lavi; Kari Niemelä; Philippe Gabriel Steg; Ivo Bernat; Yawei Xu; Warren J Cantor; Christopher B Overgaard; Christoph K Naber; Asim N Cheema; Robert C Welsh; Olivier F Bertrand; Alvaro Avezum; Ravinay Bhindi; Samir Pancholy; Sunil V Rao; Madhu K Natarajan; Jurriën M ten Berg; Olga Shestakovska; Peggy Gao; Petr Widimsky; Vladimír Džavík Journal: N Engl J Med Date: 2015-03-16 Impact factor: 91.245
Authors: Sanjit S Jolly; John A Cairns; Salim Yusuf; Brandi Meeks; Peggy Gao; Robert G Hart; Sasko Kedev; Goran Stankovic; Raul Moreno; David Horak; Saleem Kassam; Michael J Rokoss; Raymond C M Leung; Magdi El-Omar; Hannu O Romppanen; Ashraf Alazzoni; Aiman Alak; Anthony Fung; Dimitrios Alexopoulos; John D Schwalm; Nicholas Valettas; Vladimír Džavík Journal: Eur Heart J Date: 2015-06-29 Impact factor: 29.983
Authors: Michael Megaly; Mehmet Yildiz; Edward Tannenbaum; Brynn Okeson; Marshall W Dworak; Ross Garberich; Scott Sharkey; Frank Aguirre; Mark Tannenbaum; Timothy D Smith; Timothy D Henry; Santiago Garcia Journal: J Am Heart Assoc Date: 2021-11-24 Impact factor: 5.501